drugset
drugset / Trial / NCT04180501

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

NCT04180501 ↗

Phase 2 Unknown 25 enrolled Xiaorong Dong
NaSingle-groupOpen-labelTreatment

Summary

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

Timeline

Start
2019-11
Primary completion
2021-09
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody — —

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma